MENLO PARK, Calif., Feb. 23 /PRNewswire/ -- Conor Medsystems, Inc. today announced it plans to present the results for its COSTAR II U.S. pivotal clinical trial at the EuroPCR meeting in Barcelona in May.
“The last patient was followed-up in February 2007, and we expect the independent clinical research organization to commence the data analysis in March, providing sufficient time for presentation at the upcoming EuroPCR meeting,” said Michael Boennighausen, General Manager, Conor Medsystems. “We look forward to the opportunity to present these data in May.”
The COSTAR II clinical trial is a randomized, single-blind, non-inferiority study comparing Conor Medsystems’ CoStar(R) cobalt chromium paclitaxel-eluting stent with Boston Scientific’s Taxus(R) Express2 drug- eluting stent in the treatment of de novo lesions in patients with single or multi-vessel coronary artery disease. It includes 1,700 patients from more than 70 clinical sites.
Johnson & Johnson acquired Conor Medsystems in February of this year.
About Conor Medsystems
Conor Medsystems develops innovative controlled vascular drug delivery technologies, and has primarily focused on the development of drug-eluting stents to treat coronary artery disease. For further information on Conor Medsystems and controlled vascular delivery, visit http://www.conormed.com.
The CoStar(R) stent is not available for sale in the U.S. The CoStar(R) stent is an investigational device limited by law to investigational use in the U.S.
Conor Medsystems, Inc.
CONTACT: Media, Christopher Allman, office, +1-786-313-2303, mobile,+1-305-586-6024, or Analysts, Stan Panasewicz, Johnson & Johnson, office,+1-732-524-2524
Web site: http://www.conormed.com/
